Lanean...
Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
The dipeptidyl peptidase-4 inhibitor (DPP-4i) alogliptin is an oral, antidiabetic treatment that is approved in many countries to treat patients with type 2 diabetes mellitus (T2DM), including the USA, Europe, and Japan. Alogliptin is efficacious both as monotherapy and as add-on/combination therapy...
Gorde:
| Argitaratua izan da: | Drug Saf |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Springer International Publishing
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6834733/ https://ncbi.nlm.nih.gov/pubmed/31654243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40264-019-00857-8 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|